Lung Cancer Alliance Applauds Launch of Innovative Trial at National Cancer Institute

WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed.

"This trial demonstrates the power of CT screening to open new research windows on critical problems, such as recurrence, that have eluded solutions to date," she said.

Few trials have been conducted on earlier stage lung cancer because so few lung cancer patients have been diagnosed at early stage.  With wider availability of low dose CT, this will change.  

This trial, the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, will test whether erlotinib and crizotinib, already approved as targeted therapies for EGFR positive and ALK positive types of late stage lung cancer, can effectively block recurrence when those cancers are found at an earlier stage.

Since the EGFR and ALK mutations are found in just 5% to 10% of lung cancers, NCI estimates that the tumors from 6,000 to 8,000 post-surgical patients would have to be tested for the mutations to yield about 600 patients eligible for the trial.

Patients whose resected tumors test positive will be given adjuvant chemotherapy and possibly radiation, and then treated with either erlotinib or crizotinib and followed for five years for recurrence.

"In this new era of CT screening for lung cancer, the number of lung cancers found at early stage will increase dramatically, making trials and new lifesaving breakthroughs like this feasible," Fenton Ambrose said.

Lung Cancer Alliance, www.lungcanceralliance.org, is the leading national organization providing hope for the lung cancer community by offering patient support, national awareness, community outreach, and advocacy to advance research into early detection and treatments for all forms of lung cancer. 

For more details on the trial please go to: http://www.cancer.gov/newscenter/newsfromnci/2014/ALCHEMISTlaunchQandA.

Media Contact:
Gabby Geier
202-742-1897
[email protected]

SOURCE Lung Cancer Alliance

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED